Dr Steven Szabo
Dr. Szabo is a neuroscientist and psychiatrist with a specialization in psychopharmacology and experimental therapeutics. He completed his PhD at McGill University, postdoctoral training at the National Institutes of Health, and psychiatry residency at Duke University. Dr. Szabo employs a translational approach to developing therapeutics with greater efficacy in disorders such as depression, anxiety, posttraumatic stress disorder, and substance abuse. He uses novel biomarker approaches in clinical trial design as a measure of neural circuit modulation and target engagement to testing of experimental drugs and devices.
I am a board-certified psychiatrist, trained neuroscientist and practicing translational psychopharmacologist that conducts industry and government funded clinical research trials. My specialty is clinical research trial design which combines neurobiological outcome measures and symptom reduction endpoints. Regulatory approval for treatment indications in psychiatry and neurology is my primary goal. Early identification of markers of treatment success that supports clinical trial design supports this mission. Bench to bedside scientific approaches to testing proof of concept treatments based on target engagement and dose-findings experiments constitutes early stage research (Phase I-II). I am co-founder of the Centers of Psychiatric Excellence (COPE), a real-world clinical consortium providing management services to a coalition of six sites delivering cutting-edge clinical care while capturing efficacy and safety outcome measures for a database registry. Multicenter phase III and phase IV clinical trials constitutes many of my research, scholarly, and clinical activities.